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Abstract
The ultimate goals of treating chronic hepatitis B (CHB) 
is prevention of hepatocellular carcinoma (HCC) and 
hepatic decompensation. Since the advent of effective 
antiviral drugs that appeared during the past two de-
cades, considerable advances have been made not only 
in controlling hepatitis B virus (HBV) infection, but also 
in preventing and reducing the incidence of liver cirrho-
sis and HCC. Furthermore, several recent studies have 
suggested the possibility of reducing the incidence of 
recurrent or new HCC in patients even after they have 
developed HCC. Currently, six medications are avail-
able for HBV treatment including, interferon and five 
nucleoside/nucleotide analogues. In this review, we will 
examine the antiviral drugs and the progresses that 
have been made with antiviral treatments in the field of 
CHB. 
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Chronic hepatitis B virus (HBV) infection is one 
of the leading causes of death across the world due 
to its worldwide distribution and potential sequelae. 
Advances in knowledge in combination with the de-
velopment of potent and effective antiviral therapy for 
chronic hepatitis B have led to decreased complications 
from the virus. Timely use of nucleotide/nucleosides 
may improve liver function and increase survival in 
patients with hepatic decompensation. Maintained sup-
pression of HBV replication with antiviral therapy halts 
the progression of liver disease, may reverse liver fibro-
sis, and can reduce the development of cirrhosis and 
hepatocellular carcinoma.
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INTRODUCTION
In the decades after World War Ⅱ, clinical and epide-
miological studies began to differentiate among various 
types of  hepatitis[1]. However, it was the discovery of  
an antigen by Blumberg and his colleagues, now known 
as hepatitis B surface antigen (HBsAg), in the serum of  
an Australian Aborigine that reacted with the antibody 
(now known to be anti-HBs) in serum of  a hemophiliac 
patient that provided the first clue[2]. Subsequent develop-
ment of  acute hepatitis in a technician in his laboratory 
provided the essential link to the illness. For his discovery 
and subsequent work on the disease progression related 
to hepatitis B virus (HBV), Blumberg received the Nobel 
WJG 20th Anniversary Special Issues (9): Hepatitis B virus
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Prize in Medicine 1976[3,4]. In 1970, Dane et al[5], identified 
the whole virus particle (Dane particle) using electron 
microscopy. In 1972, hepatitis B e antigen (HBeAg) was 
identified by Magnius et al[6]. By the early 1980’s the ge-
nome of  the virus had been sequenced and the first vac-
cine (initiated by Millman et al and developed by Hilleman 
et al) were tested[7,8]. This plasma vaccine became available 
in 1983 and was rightly designated “The First Cancer 
Vaccine” by World Health Organization. The close link 
between HBV and hepatocellular carcinoma (HCC) was 
lucidly documented by Beasley et al[9] in their historical 
prospective study of  22707 men in Taiwan (Figure 1).
Since the discovery of  the virus, our understanding 
and knowledge about the complexities of  HBV have 
grown tremendously. Chronic HBV infection is one of  
the leading causes of  death across the world due to its 
worldwide distribution and potential sequelae. People 
infected with the virus are at risk of  developing hepatic 
decompensation, liver cirrhosis and HCC with 15% to 
40% of  individuals developing serious sequelae in their 
lifetime[9]. Despite the implementation of  effective uni-
versal vaccination programs, over 300 million people are 
still chronically infected with HBV worldwide with 75% 
of  infected individuals residing in the Asia-Pacific re-
gion[10,11]. 
Increased knowledge of  the natural history of  chronic 
hepatitis B (CHB) and clinical data demonstrating im-
proved outcomes with medical interventions have led to 
publication of  various treatment guidelines aimed at pro-
viding direction regarding initiation/on-treatment man-
agement of  antiviral therapy and monitoring of  outcome 
measures. These advances in knowledge in combination 
with the development of  potent and effective antiviral 
therapy for CHB have led to decreased complications 
from the virus[12]. In this review, we will discuss the ad-
vances in the understanding of  the natural history of  
CHB and the progress of  anti-HBV treatment over the 
past two decades.
HEPATITIS B VIRUS
HBV belongs to a group of  closely related DNA viruses 
termed Hepadnaviruses[13-15]. This family of  viruses has 
a strong preference for infecting liver cells and has a 
similar life cycle in their hosts. The virus consists of  a 
nucleocapsid and an outer envelope composed mainly of  
three HBsAgs, which play a central role in the diagnosis 
of  HBV infection. The nucleocapsid contains hepatitis B 
core antigen (HBcAg), a DNA polymerase-reverse tran-
scriptase, and the viral genome[16]. The genome consists 
of  a partially double-stranded circular DNA molecule of  
about 3200 base pairs in length. The pre-surface 1/pre-
surface 2 and surface genes code for the various HBsAgs. 
The protein encoded by the pre-core/core gene under-
goes post-translational modification to yield HBeAg, 
which is a seromarker for high viral replication[16]. The 
viral DNA polymerase-reverse transcriptase is encoded 
by the polymerase gene and is of  central importance for 
viral replication. Different from all known mammalian 
DNA viruses, hepadnaviruses replicate using a reverse 
transcription of  an RNA intermediate[17-19]. Based on this 
unique replication cycle of  HBV, antiviral therapeutic 
strategies have been mainly aimed at the reverse tran-
scription of  HBV RNA with nucleotide/nucleoside ana-
logues[20].
The presence of  HBV DNA in serum is the best in-
dication of  active viral replication. Antibody to HBsAg is 
produced in exposure to the envelope antigen and con-
fers protective immunity. Antibody to HBcAg is detect-
able in all patients who have ever been exposed to HBV. 
However, unlike antibody to HBsAg, this antibody is 
not protective, but can be helpful in distinguishing acute 
from chronic infection if  IgM antibody (anti-HBc IgM) 
is present. Antibody to HBeAg appears when the antigen 
has been cleared and the virus is no longer replicating or 
has reduced replication[12].
PATHOGENESIS AND CARCINOGENESIS 
OF HEPATITIS B
Liver injury in CHB is the result of  the host’s immune re-
sponses against HBV; an HLA-class Ⅰ antigen-restricted, 
cytotoxic T lymphocyte-mediated response against HBV 
antigens expressed on hepatocytes would result in apop-
tosis and necrosis of  the hepatocytes[21]. Accordingly, 
CHB is a dynamic state of  interactions among HBV, the 
patient’s hepatocytes and the immune system. Based on 
these interactions, the natural course of  CHB can be 
divided into different changing phases, although not all 
patients go through all of  the phases (Figure 2)[22].
The first phase is the “immune tolerant phase” which 
consists of  HBeAg seropositivity, high viral loads, but 
with a normal serum alanine aminotransferase (ALT) 
and near-normal liver histology. Adult-acquired chronic 
HBV infection usually has a very short “immune tolerant 
phase”. In contrast, the perinatally or early childhood-
acquired chronic HBV infection has a long “immune tol-
erant phase”[22-24]. The “immune clearance phase” usually 
develops during adolescence or adulthood. This phase 
is characterized by positive HBeAg, high serum HBV 
levels and increased ALT levels, sometimes complicated 
by hepatic decompensation[21]. These events may lead to 
progression to fibrosis or development of  cirrhosis in 
some patients during the HBeAg-positive phase, but may 
also result in a declining serum HBV DNA level and may 
eventually lead to HBV DNA seroclearance and HBeAg 
seroconversion to its antibody (anti-HBe) in most pa-
tients. A 3-year clinical study in patients with chronic 
hepatitis B, or patients in the “immune clearance phase”, 
showed that cirrhosis developed at an estimated annual 
incidence of  2.1%, being higher in those seropositive for 
HBeAg at entry (2.4%/year)[25]. The estimated annual 
incidence of  spontaneous HBeAg seroconversion was 
reported to be 2%-15%, depending on factors such as 
age, ALT level and HBV genotype[26,27]. Following HBeAg 
seroconversion, most of  the patients enter an “inactive 
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phase” with sustained normal serum ALT, low serum 
HBV DNA and no or minimal necro-inflammatory histo-
logical changes, although some of  them may have already 
developed advanced fibrosis or cirrhosis[27-29]. Spontane-
ous HBsAg seroclearance may occur several years after 
HBeAg seroconversion at an incidence of  0.7%-2.4% per 
year depending on age at time of  infection[29].
As early as the 1970’s, chronic infection with the HBV 
was associated with the development of  HCC. A power-
ful substantiation of  the association between HBV infec-
tion and HCC was the results of  a prospective cohort 
study reported by Beasley et al[9] in 1981. These investiga-
tors followed more than 22000 male municipal workers 
in Taiwan and found that those who were seropositive 
for HBsAg had rates of  HCC that were significantly 
greater than were the rates in uninfected controls. They 
calculated the relative risk for HCC among those who 
were HBV-infected to be 63 compared to uninfected 
controls. More recent cohort studies have confirmed 
the high risk of  HCC in HBsAg-positive individuals as 
originally identified in the Beasley study. An example 
is the Haimen City cohort that included about 11000 
HBsAg-positive subjects followed over a mean period 
of  8 years[30]. The mechanism by which HBV infection 
causes HCC is not completely understood. Evolution to 
HCC may be the direct effect of  the virus itself, or it may 
be an indirect effect, through the process of  the inflam-
mation, regeneration and fibrosis associated with cirrho-
sis due to the HBV infection[31,32]. HBV DNA has been 
shown to become integrated within the chromosomes 
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1965: Discovery of 
HBV (HBsAg)
1980: Epidemiology, 
pathogenesis/carcinogenesis/
genome sequence
1970: Dane 
particle identified
1972: HBeAg 
discovered
1983: HBV vaccine
1998: Development 
of antiviral drugs
Prevention of progression of liver disease including HCC with antiviral therapy
Prevention of recurrence of HCC with antiviral therapy
Dr. Baruch S Blumberg discovered an Antigen in the blood of Australian 
Aborigine and named Australia Antigen which was found to be HBsAg. 
Made the first HBV vaccine (plasma vaccine Heptavax B). Received Nobel 
Prize in Medicine in 1976.
Dr. R Palmer Beasley conducted a study of over 22000 government 
workers found that risk of liver cancer is 60 times higher in chronic HBV 
infected persons.
Figure 1  Progress in the field of hepatitis B virus. HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; HCC: Hepatocellular carcinoma.
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Asia, HBV is the leading cause of  chronic hepatitis, cir-
rhosis, and HCC[37]. The HBV carrier rates in Asia have 
been reported to be as high as 20% in the male popu-
lation of  Guangxi Province, China[38]. A recent study, 
conducted in China, showed that HBV carrier rates have 
fallen to 7.2% in regions where hepatitis B vaccination 
programs had been implemented[39]. In South Korea, the 
HBV carrier rates ranged from 5.0% to 8.6% in the 1970s 
and 1980s and have subsequently declined to 3.7%-5.7% 
as a result of  national vaccination programs[40,41]. In other 
parts of  Asia, the HBV infection rates remain high, par-
ticularly in countries in which vaccine programs have not 
yet been implemented. Notably, the HBsAg rates among 
Asians residing in the United States are similar to rates 
reported in their countries of  origin, especially in first-
generation immigrants to the United States[42-45]. There-
fore, the disease burden from HBV, including mortality 
from liver disease progression and development of  HCC, 
remains a major health problem among Asian Americans 
with CHB.
PROGRESSION OF HEPATITIS B 
TREATMENT
Currently, six treatments are approved for hepatitis B, 
including interferon (IFN) (two formulations: IFN and 
PEG-IFN) and five nucleotide/nucleoside analogues (la-
mivudine, adefovir, entecavir, telbivudine and tenofovir) 
(Figures 3 and 4)[36,46]. The aim of  hepatitis B treatment 
is to achieve sustained viral suppression of  HBV replica-
tion. With viral suppression, the ultimate goal would be 
prevention of  cirrhosis and HCC. Response to treatment 
of  infected hepatocytes, the integration of  viral genetic 
material occurring in a critical location within the cellular 
genome. The hepatitis B x gene (HBx) product has been 
implicated in causing HCC because it is a transcriptional 
activator of  various cellular genes associated with growth 
control[32,33]. The HBx gene expression is also associated 
with activation of  the Ras-Raf-MAP kinase pathway, an 
important cellular pathway that has been implicated in 
hepatocarcinogenesis. 
HBsAg seroclearance usually confers protection against 
HCC but may still carry a risk for HCC although at a 
very low rate and usually in patients in whom cirrhosis or 
superinfection with other viruses had already developed 
before HBsAg seroclearance[34,35]. Studies further indicate 
that serum HBV DNA level is associated with cirrhosis 
and HCC development in a dose-dependent manner start-
ing from serum HBV DNA level[34-38]. These findings 
suggest that HBV replication, with subsequent immune-
mediated liver injuries, is the primary driving force for 
liver disease progression. It has also been identified that 
patients of  Asian background are at higher risk for HCC 
because they are more likely to have been infected early 
in life and carcinogenic processes could have taken place 
earlier[37]. This may explain why some patients even with 
well suppressed viral replication still develop HCC.
EPIDEMIOLOGY OF HEPATITIS B 
INFECTION
As stated earlier, HBV infection is common and clini-
cally consequential worldwide. In endemic countries, an 
estimated 50 million new cases are diagnosed annually. In 
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Figure 2  Five phases of chronic hepatitis B. Adapted from Tong et al[37]. ALT: Alanine aminotransferase; Anti-HBc: Hepatitis B core antibody; HBsAg: Hepatitis B 
surface antigen; HBeAg: Hepatitis B e antigen; Anti-HBe: Hepatitis B e antibody. 
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is judged based on decrease in serum HBV DNA level, 
loss of  HBeAg with or without seroconversion to anti-
HBe, loss of  hepatitis B surface antigen (HBsAg) with or 
without seroconversion to HBs antibody, normalization 
of  serum ALT levels, and a decrease in hepatic inflamma-
tion on liver biopsy[46,47].
The importance of  monitoring individuals with low-
serum HBV DNA and normal ALT levels regardless 
of  their HBeAg status has also become recognized in 
recent years. Serial ALT and HBV DNA monitoring 
every 3 mo for 1 year after the initial diagnosis and 6-12 
mo thereafter is usually recommended to detect intermit-
tent flares of  hepatitis B[37,48]. This regimen is also useful 
to differentiate chronic active HBeAg negative hepatitis 
from inactive carriers in recently diagnosed HBV carri-
ers. Treatment should be initiated regardless of  the level 
INFa
1990                                   1998                         2002          2005    2006                   2008                2013
Lamivudine Adefovir
Peg IFN
Entecavir
Telbivudine
Tenofovir
Figure 3  Timeline of approved therapies for chronic hepatitis B. IFN: Interferon.
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of  viremia if  active inflammation is also detected on 
liver biopsy[37,47,49]. In the case of  HBeAg negative CHB, 
treatment is continued indefinitely until HBsAg becomes 
undetectable. Nonetheless, close follow-up is important, 
and prompt retreatment is necessary if  elevation of  HBV 
DNA and ALT levels are observed[37]. Therefore, achiev-
ing maximum viral suppression without the development 
of  antiviral drug resistance, reducing progression to cir-
rhosis and decreasing the risk of  developing HCC are the 
primary treatment endpoints.
Interferon
In 1991, conventional IFNa-2a was the first successful 
treatment approved for CHB with widespread use. Its 
major mechanism of  action is immune modulation, al-
though there is also a weak anti-viral effect[50]. Peg IFNa-
2a replaced standard IFN in 2005 due to improved phar-
macokinetic properties and a less demanding injection 
schedule with comparable efficacy. Long-term follow-
up of  patients treated with conventional IFN therapy 
showed that responders had a decreased incidence of  
hepatic decompensation and HCC, and improved overall 
survival compared with non responders[51-53]. Forty-eight 
weeks of  therapy with Peg IFN results in a 27% rate of  
HBeAg seroconversion and 25% rate of  loss of  HBV 
DNA. Six months after discontinuation of  therapy, the 
HBeAg seroconversion rates increased to 32%. Loss of  
HBsAg with the appearance of  anti-HBs occurred in 
4%-6% of  patients after 1 year of  treatment and 6 mo of  
post treatment follow-up[51,54,55]. Even after discontinua-
tion of  IFN therapy, 12%-65% of  patients lost HBsAg 
within 5 years of  HBeAg loss. This results in the highest 
rate of  off-treatment sustained response after 1 year of  
therapy[53,54]. Achieving early virological response, defined 
as > 2 log10 drop in serum HBV DNA or suppression to 
levels below 105 copies/mL in the first 2 wk of  therapy, 
is associated with induction of  long-term remission after 
stopping therapy[56,57]. 
Despite the fixed duration of  Peg IFN therapy and 
the lack of  antiviral drug resistance compared with oral 
agents, the use of  Peg IFN only accounts for no more 
than 10% of  all prescriptions for the treatment of  CHB 
in the United States[54]. This low rate can be explained by 
the drug’s substantial side effect profile and the need for 
administration by injection.
Lamivudine
Lamivudine (LAM) was the first nucleoside analogue re-
verse transcriptase inhibitor that was approved for use by 
the United States Food and Drug Administration (FDA) 
in 1998. Although it is not as used as commonly today 
due to the presence of  better oral agents with higher 
genetic barrier to resistance; it played a major role in the 
transition CHB treatment and allowed reduction in cir-
rhosis and risk of  HCC to be achieved with some suc-
cess. 
One-year therapy with lamivudine is associated with 
16%-18% rate of  HBeAg seroconversion; the HBeAg 
seroconversion rate increases to 50% with 5 years of  
therapy[58-60]. LAM therapy also results in 60%-70% HBV 
DNA suppression in HBeAg-negative CHB after 1 year 
of  therapy[56]. The durability of  response is lower than 
the interferon therapy regardless of  the HBeAg status 
and has been reported to range between 50% and 80% 
for HBeAg-positive CHB and 20%-25% for HBeAg-
negative CHB patients. 
Treatment of  HBV with LAM has been shown to 
slow the rate of  development of  fibrosis, as well as 
decrease of  HCC incidence[60-62]. Use of  LAM is associ-
ated with a significant risk of  development of  resistance 
with prolonged use. Five years of  therapy can lead to 
65%-70% rate of  resistance[59]. However, thorough re-
view of  studies investigating the LAM resistance during 
CHB treatment revealed a diverse range of  methodolo-
gies to assess resistance[63]. Studies that use purely geno-
typic methods report resistance rates at 1 year ranging 
from 14% to 32%. However, these may overestimate 
clinically relevant resistance. Studies that use virologic 
resistance report lower one year resistance rates, rang-
ing from 6.4% to 15.4% and may provide more relevant 
measure of  resistance. When comparing resistance rates 
with antiviral drugs in CHB, it is important to consider 
the methodology and definition of  resistance used[63]. In 
addition, baseline HBV DNA was closely related to the 
resistance rate[64] and HBV DNA level at 6 mo on LAM 
therapy was an important predictor for LAM resistance 
at one year and later[65]. 
The largest and most compelling study suggesting 
that antiviral treatment might decrease the risk of  HCC 
was a randomized, controlled trial of  LAM vs placebo 
in patients with advanced chronic hepatitis B and high 
serum levels of  HBV DNA[60]. The primary outcome of  
the study was progression of  liver disease, including an 
increase in Child-Pugh score, bleeding from esophageal 
varices and the development of  HCC. The study was 
halted early because of  a distinct benefit for the group on 
LAM treatment compared to the placebo group. Instead 
of  continuing the study for intended 5 years, all received 
LAM at the end of  3 years on trial. In this study, at year 3, 
the rate of  HCC was 3.9% among LAM recipients vs 7.4% 
among placebo recipients (P = 0.047). Other retrospec-
tive studies observed similar results[61,66].
Adefovir dipivoxil
Adefovir dipivoxil (ADV) was the first nucleotide ana-
logue approved in United States in 2002 for the treatment 
of  CHB. The arrival of  this agent provided new insights 
into the treatment of  CHB. ADV did not only have in-
creased antiviral potency but also had an intrinsic stereo-
scopic structure which was an important factor against 
the emergence of  viral resistance. 
One year of  therapy with ADV leads to a 12% rate 
of  HBeAg seroconversion and 53% rate of  histologi-
cal improvement in HBeAg-positive patients[67]. Once 
HBeAg seroconversion occurs, it is sustained in 91% of  
patients[68]. Like LAM, HBeAg-negative patients require 
Halegoua-De Marzio D et al . Progress in hepatitis B treatment
407 January 14, 2014|Volume 20|Issue 2|WJG|www.wjgnet.com
therapy indefinitely with ADV, and resistance is also a 
problem with prolonged ADV use. Persistence of  vire-
mia after 48 wk of  therapy is linked to development of  
resistance[69]. Resistance rates of  0%, 3%, 18% and 29% 
have been reported at 1, 2, 4 and 5 years of  therapy[70]. 
These high resistance rates and its potential renal toxic-
ity have lead to declining use of  ADV in light of  newer 
therapeutic agents. Furthermore, ADV was highly effec-
tive for LAM resistant HBV[71,72].
Entecavir
During the period between 1998 and 2004, LAM and 
ADV for treatment naive CHB and ADV for LAM-resis-
tant CHB were the main treatment strategies available for 
CHB. In 2005, entecavir (ETV), a nucleoside analogue, 
entered the arena when it was approved in United States. 
It is a potent inhibitor of  HBV polymerase at a dose of  
0.5 mg daily resulting in 6.98 log10 copies/mL decrease 
in HBV DNA levels compared to a 5.4 log10 copies/mL 
reduction with LAM[73]. In clinical studies, patients who 
received ETV for 52 wk achieved superior virological 
response, with HBV DNA < 400 copies/mL (67% vs 
36%), histological improvement (72% vs 62%) and nor-
malization of  ALT (78% vs 70%) compared with those 
who received LAM[73]. However, there was no difference 
between ETV and LAM in achieving HBeAg serocon-
version (21% vs 18%). ETV is also superior to LAM in 
HBeAg-negative patients, but requires indefinite treat-
ment to maintain viral suppression to prevent relapse[74-76]. 
ETV demonstrates better virological suppression (91% vs 
73%) and improved histology (70% vs 61%). In addition, 
analysis of  two studies of  patients who received continu-
ous ETV for up to 5 years revealed that 94% of  patients 
continue to have HBV DNA < 300 copies/mL at 5 
years[76]. 
In long term studies, up to 96% of  patients (mainly 
HBeAg-positive CHB) had histological improvement 
and 88% of  the patients had improvement in fibrosis 
score after 6 years of  ETV therapy; this holds true even 
in patients with cirrhosis[77]. ETV has also been shown to 
be superior to ADV in achieving rapid viral suppression 
within 2 wk of  therapy. Even though a 48-wk therapy 
with ETV compared with ADV was associated with a 
higher rate of  HBV clearance (58% vs 19%) and ALT 
normalization (76% vs 63%), there was no difference in 
the rate of  HBeAg loss (18% vs 22%) and HBeAg sero-
conversion (15% vs 22%)[78]. 
One of  the most important differences from LAM 
and ADV is that, ETV has a high genetic barrier with 
a very low incidence of  resistance. The cumulative in-
cidence rate of  resistance after 6 years of  therapy in 
nucleoside-naïve patients remains low at 1.2%[79,80]. The 
low resistance rate is related to both profound viral sup-
pression and the requirement of  at least 3 sites of  genetic 
mutations to confer resistance. However, the chance for 
ETV resistance is much higher in patients who already 
developed LAM resistance[80]. ETV therapy has also been 
associated with HBsAg loss, improvement of  liver histol-
ogy, decreased risk of  HCC and very low to undetectable 
HBV DNA levels[81,82]. The ability to decrease the inci-
dence of  HCC in patients with CHB has been the most 
exciting attributes of  antiviral therapy. Recent report 
from Hosaka et al[83] compared the incidence of  HCC 
in 472 ETV-treated patients and 1143 non-treated HBV 
patients. The drug mutation resistance was 0.8% (4/472) 
in the ETV group. The cumulative HCC incidence rates 
at 5 years were 3.7% and 13.7% for the ETV and control 
groups, respectively (P < 0.001). The treatment effect was 
found to be greater in patients at higher risk of  HCC.
Telbivudine
While newer treatments for LAM-resistant disease were 
still under investigation, telbivudine (TLV), another 
nucleoside analogue was approved by the FDA in 2006 
for treatment of  chronic CHB. In HBeAg-positive CHB 
patients, the rate of  HBeAg seroconversion with TLV 
therapy was 22% and 30% at 1 and 2 years respectively. 
Viral suppression was limited to HBV DNA levels of  < 
300 copies/mL after 1 and 2 years of  therapy in 60% and 
56% of  HBeAg-positive patients[84]. In HBeAg-negative 
CHB patients, HBV suppression was noted in 88% and 
82% of  patients at 1 and 2 years of  therapy, respective-
ly[84,85]. Resistance to TLV has been reported to be 21.6% 
in HBeAg-positive patients and 8.6% in HBeAg-negative 
patients after 1 and 2 years of  therapy respectively. Al-
though TLV barrier to antiviral resistance is higher then 
LAM, is not recommended as a first-line agent[37,48,51]. 
Although this treatment is not used often due to its high 
rate of  resistence it is effective and safe for the preven-
tion of  mother-to-child transmission of  HBV from 
chronically infected mothers with a high degree of  infec-
tivity late in pregnancy.
Analysis of  the baseline characteristics of  the pa-
tients enrolled in the GLOBE trial revealed important 
predictive factors of  response to therapy. The strongest 
predictors of  achieving a good response to TLV therapy 
in HBeAg-positive patients were serum HBV DNA < 9 
log10 copies/mL, or ALT ≥ 2 times the ULN at baseline 
with undetectable serum HBV DNA at week 24 of  ther-
apy[86]. Extensive review of  TLV for treatment of  hepati-
tis B indicated that there was a specific group of  patients 
who are likely to achieve good therapeutic response with 
TLV. Patients with low baseline HBV DNA who could 
achieve negative HBV DNA at week 24 had the best 
outcome with TLV[87]. With this data, LAM and TLV can 
be used in countries where cost is a major concern by 
selecting patients with favorable baseline HBV DNA and 
ALT levels. Another important aspect of  TLV is its reno-
protective effect as recently reported by Gane et al[88]. In 
approximately 2500 patients treated with TLV, there was 
a trend towards in increased GFR in both compensated 
and decompensated CHB. The mechanism of  this reno-
protective effect by TLV is unknown. 
Tenofovir
Rescue therapy for patients with viral resistance to the 
nucleoside analogues was the usage of  adefovir until 
2008 when, tenofovir disoproxil fumarate (TDF), the 
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second nucleotide analogue was approved for the treat-
ment of  CHB. It is structurally related, but more potent 
than ADV. Forty-eight weeks of  TDF compared with 
ADV therapy in HBeAg-positive CHB resulted in more 
patients achieving viral suppression defined as < 400 
copies/mL (76% vs 13%), normalization of  ALT (68% 
vs 54%), histological improvement (67% vs 12%) and 
HBsAg loss (3.2% vs 0%)[89]. Data from the TDF trials 
revealed an excellent durability of  response, with a viral 
suppression (HBV DNA < 400 copies/mL) of  99% 
and 100% in HBeAg-negative and HBeAg-positive CHB 
respectively after 4 years of  therapy[90,91]. Sub-analysis of  
the Asian subset of  145 patients revealed similar efficacy 
(97%) in achieving viral suppression defined as HBV 
PCR < 400 copies/mL[92]. Four years of  TDF therapy 
has led to HBeAg loss in 41% of  patients and HBeAg 
seroconversion in 29%[91]. TDF is also superior to ADV 
in achieving increased viral suppression (93% vs 63%), 
an improved inflammatory score and viral suppression 
(71% vs 49%) in a phase Ⅲ study of  HBeAg-negative 
patients[89]. However, besides profound viral suppres-
sion, the most impressive characteristic of  TDF is that 
no resistance has been detected to date with 5 years of  
follow up[92,93]. Due to these excellent features, TDF is 
recommended as first line agent for treatment-naïve CHB 
patients. Furthermore, treatment with TDF for 5 years 
showed regression of  cirrhosis in 74% of  those who 
showed cirrhosis at baseline[94].
Emtricitabine
Emtricitabine is a nucleoside analogue structurally similar 
to LAM. Emtricitabine was approved by the FDA since 
2003 for treatment of  HIV infection and is not approved 
by the FDA for CHB. It is currently being studied as an 
add-on to TDF therapy in the form of  Truvada (tenofovir 
300 mg/emtricitabine 200 mg). Like lamivudine, its use 
as monotherapy for treatment of  CHB is limited by its 
intermediate genetic barrier to resistance. Two years of  
emtricitabine therapy is associated with 13% risk of  de-
velopment of  resistance[95]. 
A randomized trial in ADV-experienced patients 
showed equal efficacy in viral suppression to < 400 cop-
ies/mL between tenofovir and Truvada at 24 wk of  
therapy[96]. After 24 wk in the randomized arm, patients 
were switched to open label Truvda if  they had detect-
able HBV DNA defined as > 400 copies/mL. Eighty one 
per cent of  patients in each treatment arm achieved se-
rum HBV DNA < 400 copies/mL at the end of  week 48 
according to intention-to-treat analysis[96]. The presence 
of  baseline ADV resistance or LAM resistance did not 
impact the efficacy of  TDF nor Truvada. Both TDF and 
Truvada were equivalent through week 168 of  therapy in 
achieving viral suppression at a rate of  82%, independent 
of  pre-existing ADV or LAM-resistant mutations[97]. 
ROLE OF ANTIVIRALS IN PREVENTION 
OF HCC RECURRENCE
With the advent of  antiviral therapy, it is now possible 
to reduce inflammation, regress cirrhosis and reduce the 
incidence of  HCC in patients with CHB. The incidence 
of  HCC recurrence after resection of  HBV-related HCC 
is high. Newer data has shown that there is a role for 
antiviral therapy for those who have already developed 
HCC. Since 2005, there have been retrospective studies, 
small and large in numbers that showed improvement 
of  survival in patients who received concomitant antivi-
ral therapy after curative liver resection and local tumor 
ablation[98-102]. Treatment with nucleoside/nucleotide ana-
logues may prevent de novo primary tumors and further 
progression of  liver disease, thereby decreasing recurrent 
HCC. Recent large cohort studies further confirmed the 
benefit of  antiviral therapy in this group of  patients with 
decrease in mortality with the antiviral treatment[103,104]. 
The longest survivors of  those who benefited from an-
tiviral therapy following the existing tumor ablation have 
reached over 12 years (Hann et al, personal communica-
tion). This novel treatment strategy may offer a signifi-
cant alternative to liver transplantation to relieve the cur-
rent graft shortage.
VIROLOGIC BREAKTHROUGH, 
COMPLIANCE AND SAFETY OF 
TREATMENT
As noted above, the development of  anti-viral resistance 
is a barrier in achieving successful therapy in CHB. In 
large retrospective review of  11000 CHB patients on 
nucleoside/nucleotide therapy, mean adherence rate 
to therapy was 87.8% with 1-year persistence of  81%. 
Although adherence to CHB therapy is high, new and 
younger age patients tend to be less compliant[105]. In a 
study of  148 CHB patients on nucleoside/nucleotide 
therapy with mean follow-up of  3 years, 39 patients had 
at least one virologic rebound with 38% having no geno-
typic resistance and 10 patients with further HBV DNA 
decline while continued on current re-treatment[106]. 
Medication non-adherence is a common cause of  in-
termittent virologic rebound and should be addressed 
before changing therapy. In a study of  84 patients treated 
with LAM, ADV, or ETV who stopped therapy after 
reaching defined endpoints, 42% of  HBeAg-positive and 
47% HBeAg negative patients had virologic relapse with 
HBV DNA more than 1000 copies/mL at a mean of  4.3 
mo[107]. 
Concerns about the possible lose of  bone mineral 
density (BMD) and has been raised from the results of  
clinical studies on CHB treatment[108-111]. BMD loss has 
been reported in chronic liver disease. However, acceler-
ated BMD loss has been reported in patients specifically 
on TDF[108]. This BMD loss has raised concerns regarding 
the long term safety of  TDF. BMD should be monitored 
in patients on TDF with bone density scans and factors 
that also contribute to bone loss should be given consid-
eration when selecting a treatment option for CHB[108,109]. 
Like BMD, renal function is frequently impaired in pa-
tients with compensated CHB. These oral antiviral agents 
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are all primarily eliminated unchanged through renal 
route. Therefore, inpatients with renal insufficiency, dose 
reduction and/or increased dose intervals are recom-
mended. Renal impairment is frequent after long-term 
treatment with adefovir[110]. Similarly, a decrease of  eGFR 
has been observed in retrospective cohorts of  CHB pa-
tients during long-term tenofovir or entecavir-treated[111].
CONCLUSION
Although a vaccine has been available for hepatitis B 
since 1982, this chronic infection is still far from eradi-
cated across the world. Timely use of  nucleotide/nucleo-
sides may improve liver function and increase survival in 
patients with hepatic decompensation. Maintained sup-
pression of  HBV replication with antiviral therapy halt 
the progression of  liver disease, may reverse liver fibrosis, 
and can reduce the development of  cirrhosis and HCC. 
Due to the availability of  effective and potent treatment 
options for HBV, there has been a decrease in the pro-
portion of  annual liver transplants performed for this 
indication[112]. However, one must remember that this can 
only achieved with an excellent compliance on the part 
of  patients, early detection of  drug resistance and correct 
choice of  medications. Nonetheless, current therapies 
may not always prevent all adverse sequela. HCC must 
be monitored using ultrasound and a-fetoprotein assays 
to improve outcomes by increasing early detection and 
the chance of  curative treatment. Developing safe and 
affordable agents as well as management strategies to im-
prove sustained HBV suppression should be the ultimate 
goal in the treatment of  chronic HBV infection.
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